SCHEMBL457922

SCHEMBL457922

CC1(C(N)=O)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31169689 0.97
SCHEMBL15304353 0.89 FFAR3 (0.43)
SCHEMBL1536078 0.88
SCHEMBL15340982 0.88 ALDH1A1 (0.43)
SCHEMBL540102 0.88
SCHEMBL20054604 0.87 FFAR3 (0.42)
SCHEMBL7632840 0.85 ALDH1A1 (0.52)
Hydrochloric Acid SCHEMBL4622019 0.85
SCHEMBL516698 0.85 ALDH1A1 (0.52)
SCHEMBL6874432 0.85 ALDH1A1 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity NOVARTIS PHARMA AG (CH) 2025-12-23 US claimed
WO-2025080593-A1 COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND PD-1 INHIBITOR OR PD-L1 INHIBITOR INCYTE CORPORATION (US) 2025-04-17 WO claimed
WO-2025080592-A1 COMBINATION COMPRISING A KRAS G12D INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2025-04-17 WO claimed
US-12247036-B2 Tricyclic compounds for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-03-11 US claimed
US-20240417410-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-12-19 US claimed
EP-3935058-B1 IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2024-08-21 EP claimed
EP-4415824-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2024-08-21 EP claimed
CN-114222744-B Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFNα response 百时美施贵宝公司 2024-06-25 CN claimed
WO-2023064857-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION (US) 2023-04-20 WO claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
WO-2005070931-A1 TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES MALLINCKRODT INC. (US) 2005-08-04 WO claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 WO claimed
US-20040142981-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-07-22 US claimed
US-20040110802-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-06-10 US claimed
WO-2004018461-A2 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
EP-1305277-A2 PROCESS FOR THE PREPARATION OF ALKYL 1-METHYLCYCLOPROPANECARBOXYLATE EASTMAN CHEMICAL COMPANY (US) 2003-05-02 EP claimed
US-6552217-B2 Process for the preparation of alkyl 1-methylcyclopropanecarboxylate EASTMAN CHEMICAL COMPANY 2003-04-22 US claimed
WO-2002010116-A2 PROCESS FOR THE PREPARATION OF ALKYL 1-METHYLCYCLOPROPANECARBOXYLATE EASTMAN CHEMICAL COMPANY (US) 2002-02-07 WO claimed
US-20020016493-A1 Process for the preparation of alkyl 1-methylcyclopropanecarboxylate EASTMAN CHEMICAL COMPANY 2002-02-07 US claimed